At least 4 in 10 Long-COVID Patients Report Sympto
Post# of 138
(Total Views: 188)
Posted On: 06/07/2022 4:36:43 PM
At least 4 in 10 Long-COVID Patients Report Symptoms Akin to Fibromyalgia
Tonix Pharmaceuticals recently released data showing that more than 40% of patients living with long COVID usually experience multisite pain much like fibromyalgia. Long COVID occurs when individuals who have been infected with the SARS-CoV-2 virus, which is known to cause the coronavirus, experience long-term effects from their infection.
The data was compiled from a retrospective database study that involved more than 50,000 patients who were experiencing symptoms of long COVID. The study found that a high number of participants used opioids to help manage the pain.
In the release, Tonix Pharmaceuticals CEO Seth Lederman stated that the analysis was carried out to determine the feasibility and nature of the company’s TNX-102 SL phase II study, which would involve long-COVID patients who suffered fibromyalgia-like pain.
Lederman also explained that more than 40% of the patients included in the sample presented with multisite pain, which suggested that more participants will be recruited to test the effects of their formulation in the treatment of this condition.
For their research, the scientists conducted an analysis of data obtained from the TriNetXDataworks USA network. This network contains medical records from more than 40 healthcare facilities. Out of one million patients in the network who had been diagnosed with the coronavirus infection, roughly 50,000 of them had presented with symptoms of long COVID between three to six months after an acute infection of COVID-19.
The researchers observed that at least 35% of patients with multisite pain used opioids to manage the pain, in comparison with about 20% of those who didn’t experience any pain. They also found that the use of opioids increased when insomnia or fatigue was present.
In the release, the company’s CEO stated that the company’s discoveries suggested that the group made up of patients with long COVID who suffered fibromyalgia-like pain represented a considerable portion of the population, which was underserved.
He added that high levels of opioid use also revealed the urgency to offer effective non-opioid analgesics which targeted widespread pain. This is mainly because opioids are highly addictive with higher doses also slowing an individual’s heart rate and breathing, which may lead to death.
Recently, Tonix Pharmaceuticals announced that its investigational new drug application for its TNX-102 SL formulation had been cleared for use in patients whose symptoms of long COVID were overlapping with fibromyalgia. The company plans to begin its phase 2 trial for the formulation before the end of this year’s second quarter.
Tonix isn’t the only company engaged in finding remedies for such diseases. Other entities, such as Silo Pharma Inc. (OTCQB: SILO), are also pursuing their own lines of drug development so that patients can have a remedy that actually works in easing or ending their symptoms.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Tonix Pharmaceuticals recently released data showing that more than 40% of patients living with long COVID usually experience multisite pain much like fibromyalgia. Long COVID occurs when individuals who have been infected with the SARS-CoV-2 virus, which is known to cause the coronavirus, experience long-term effects from their infection.
The data was compiled from a retrospective database study that involved more than 50,000 patients who were experiencing symptoms of long COVID. The study found that a high number of participants used opioids to help manage the pain.
In the release, Tonix Pharmaceuticals CEO Seth Lederman stated that the analysis was carried out to determine the feasibility and nature of the company’s TNX-102 SL phase II study, which would involve long-COVID patients who suffered fibromyalgia-like pain.
Lederman also explained that more than 40% of the patients included in the sample presented with multisite pain, which suggested that more participants will be recruited to test the effects of their formulation in the treatment of this condition.
For their research, the scientists conducted an analysis of data obtained from the TriNetXDataworks USA network. This network contains medical records from more than 40 healthcare facilities. Out of one million patients in the network who had been diagnosed with the coronavirus infection, roughly 50,000 of them had presented with symptoms of long COVID between three to six months after an acute infection of COVID-19.
The researchers observed that at least 35% of patients with multisite pain used opioids to manage the pain, in comparison with about 20% of those who didn’t experience any pain. They also found that the use of opioids increased when insomnia or fatigue was present.
In the release, the company’s CEO stated that the company’s discoveries suggested that the group made up of patients with long COVID who suffered fibromyalgia-like pain represented a considerable portion of the population, which was underserved.
He added that high levels of opioid use also revealed the urgency to offer effective non-opioid analgesics which targeted widespread pain. This is mainly because opioids are highly addictive with higher doses also slowing an individual’s heart rate and breathing, which may lead to death.
Recently, Tonix Pharmaceuticals announced that its investigational new drug application for its TNX-102 SL formulation had been cleared for use in patients whose symptoms of long COVID were overlapping with fibromyalgia. The company plans to begin its phase 2 trial for the formulation before the end of this year’s second quarter.
Tonix isn’t the only company engaged in finding remedies for such diseases. Other entities, such as Silo Pharma Inc. (OTCQB: SILO), are also pursuing their own lines of drug development so that patients can have a remedy that actually works in easing or ending their symptoms.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
(0)
(0)